RxDoctor Payments Data

James Bentley, MD

Ophthalmology · Dallas, TXNPI 1902894199

Payments from drug & device makers

$1,899in general payments, 2019–2025

Across 96 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$671
  • Mallinckrodt Hospital Products Inc.$157
  • Alcon$155
  • Biotissue Holdings Inc.$146
  • Aerie Pharmaceuticals, Inc.$105
  • ANI Pharmaceuticals, Inc.$88
  • plus $578 from 16 others

What the payments were for

  • Speaking & faculty fees$191%
  • Food & beverage$1,88099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,899 in reported general payments places this provider in the 45th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$53,425
Medicare patients
209
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost153$84,288
RocklatanNetarsudil Mesylat/Latanoprost125$58,451
VyzultaLatanoprostene Bunod77$40,187
RestasisCyclosporine22$37,335
Alphagan PBrimonidine Tartrate25$9,277
RhopressaNetarsudil Mesylate20$6,229
CombiganBrimonidine Tartrate/Timolol12$5,641
Travoprost36$5,350
Brimonidine Tartrate326$4,075
Latanoprost528$3,577
Bimatoprost37$3,569
Acetazolamide40$2,847
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat158$1,594
TafluprostTafluprost/Pf14$1,411
Dorzolamide Hcl44$736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$671$136,540212 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$105$64,680145 claims
Bausch & Lomb Americas Inc.Vyzulta$46$40,18777 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →